$LLY Eli Lilly Q2 Earnings
- Adj. EPS $8.38 vs. $6.31 y/y
- Rev. $22.97B, est. $20.59B
- Zepbound rev. $4.93B, est. $4.64B
- Mounjaro rev. $9.9B, est. $8.83B
- Trulicity rev. $1.22B, est. $868.8M
- Humalog rev. $410M, est. $448.5M
- Foundayo rev. $98M, est. $92M
- Committed addl. $4.5B to expand manufacturing sites
- Sees FY rev. $85.0B to $87.0B, saw $82.0B to $85.0B
- Sees FY adj. EPS $35.50 to $36.50, saw $35.50 to $37
- Raises year guidance
- Easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro forecas